Active Clinical Trial Studies
Find a Clinical Trial
Below is a list of currently active Phase I, II, III and IV trials. You can also search for a specific clinical trial using the field provided.
Clinical Trials match your criteria
-
Incidence of Surgical Site Complications Following Cesarean Delivery Closure Comparing Absorbable Subcuticular Staples with Conventional Closure
Incidence of Surgical Site Complications Following Cesarean Delivery Closure Comparing Absorbable Subcuticular Staples with Conventional Closure
-
Evolut™ EXPAND TAVR II Pivotal Trial
Evolut™ EXPAND TAVR II Pivotal Trial
-
US Selumetinib Registry
US Selumetinib Registry
-
Assert-IQTM Insertable Cardiac Monitor Post Market Study
Assert-IQTM Insertable Cardiac Monitor Post Market Study
-
A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety Study of Patients Treated with SKYTROFA (lonapegsomatropin-tcgd) (SkybriGHt)
A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety Study of Patients Treated with SKYTROFA (lonapegsomatropin-tcgd) (SkybriGHt)
-
SkyPASS: A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated with Lonapegsomatropin
SkyPASS: A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated with Lonapegsomatropin
-
Vivistim Registry for Paired VNS Therapy (GRASP)
Vivistim Registry for Paired VNS Therapy (GRASP)/(Bayfront)
-
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
-
Investigation Drug Study to Assess the Efficacy and Safety of NEXIUM for Treating Erosive Esophagitis
A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age
-
Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
